Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)
Abroad (travel likely)RecruitingPHASE2
Conditions
Head and Neck Cancer · Squamous Cell Carcinoma · Oral Cavity Cancer · Oropharyngeal Cancer · Laryngeal Cancer · Sinonasal Squamous Cell Carcinoma · HPV (Human Papillomavirus)-Associated Carcinoma · Skull Base Tumors · HPV 16 Positive Oropharyngeal Tumors (OPC)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Johns Hopkins Hospital East Baltimore, Baltimore, Maryland, United States
Contact: Principal Investigator (Nyall London, MD, Ph.D)
Study leads
Nyall R London, MD, Ph.D
Principal Investigator
Otolaryngology - Broadway